USANA Health Sciences Inc

Day range

$13.61 – $14.09

Open

$14.06

Prev close

$13.96

Volume

68.32K

Market cap

$257.93M

Shares out

18.48M

P/E

—

P/S

0.28

P/B

0.49

P/FCF

16.19

ROE

-4.2%

ROA

-3.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Credit facilityOct 5, 2026

  The Amendment makes the following changes to the Credit Agreement: ... The annual limit on the aggregate book value of property the Company and its subsidiaries may dispose of under the general basket in Section 7.05(g) of the Credit Agreement increases from $500,000 to $2,500,000.

• Preliminary resultsJan 12, 2026

  On January 12, 2026, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing preliminary net sales for the full fiscal year ended January 3, 2026

• Ceo departureJan 8, 2026

  Jim Brown stepped down as Chief Executive Officer and President of the Company. Mr. Brown will remain with the Company in an advisory role for a period at the discretion of the Board of Directors.

• Preliminary resultsOct 9, 2025

  On October 9, 2025, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing preliminary financial results for the third quarter ended September 27, 2025.

• Credit facilityJul 1, 2025

  On June 27, 2025, USANA Health Sciences, Inc. (the "Company"), as borrower, and certain of its material subsidiaries as guarantors, entered into a Third Amended and Restated Credit Agreement (the "Credit Agreement") with Bank of America, N.A. ("Bank of America"), as Administrative Agent, Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. The Credit Agreement provides for a revolving credit limit for loans to the Company of up to $75 million (the "Credit Facility"). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the Credit Facility by up to $200 million.

Days to cover

4.1

Short interest

771.59K

Avg volume

187.37K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Why Usana Health Sciences Stock Plummeted This Week
  negativeThe Motley Fool· Aug 9, 2026
• Format Innovation Reshapes a $438B Functional Market
  positiveBenzinga· Feb 13, 2026
• The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
  positiveBenzinga· Jan 19, 2026
• Women Health & Beauty Supplements Market Analysis and Growth Forecast 2026-2030
  positiveGlobeNewswire Inc.· Jan 19, 2026
• Stock Market Today: Dow Jones, Nasdaq, S&P 500 Futures Advance— Applied Digital, Stellantis, Elastic In Focus (UPDATED)
  positiveBenzinga· Oct 10, 2025